Institute of Hematology & Blood Diseases Hospital, China: all 402 studies

Page 4 of 5. Open to participants first (296), then studies with results posted, then the rest; newest registration first within each.

• An Open-label Study of GC012F in Rheumatoid Arthritis.WithdrawnNCT07315503Early Phase 1
• Data Registry in Chinese Hemophilia A and B PatientsCompletedNCT07101224
• The Mutation Profile and Prognosis in AML With IDH1/2 MutationTerminatedNCT07004816
• Growth Evaluation, Health Promotion, and Clinical Management in Children and Adolescents With ThalassemiaActive, not recruitingNCT06931912Not applicable
• Disease Burden Transition of Mucormycosis in Hematologic Malignancies Population Across Covid 19 Era: a Single-center Comparative Analysis From ChinaCompletedNCT06900114
• Daunorubicin, Cytarabine Liposomes Plus Venetoclax vs Azacitidine Plus Venetoclax in AML Patients Unfit for Intensive ChemotherapyWithdrawnNCT06770257Phase 2
• BCMA/CD3 BiTE for RRAL or NDAL Amyloidosis With Insufficient Depth of Hematologic Response After Induction TherapyWithdrawnNCT06769555Not applicable
• HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AMLActive, not recruitingNCT06744556Phase 2
• Tislelizumab with Azacitidine in the Treatment of R/R AMLWithdrawnNCT06586099Phase 1/2
• Daratumumab for T Cell ALL With MRD-positive After Standard ChemotherapyWithdrawnNCT06570915Phase 2
• Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Active, not recruitingNCT06547944Phase 1
• Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell LymphomaActive, not recruitingNCT06504199Phase 2
• A Prospective Clinical Study of CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells in the Treatment of Relapsed Refractory B-cell Non-Hodgkin LymphomaActive, not recruitingNCT06464185Phase 1/2
• Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense ChemotherapyTerminatedNCT06449482Phase 1/2
• Lusutrombopag in the Treatment of Immune Thrombocytopenia (ITP)CompletedNCT06287567Phase 2
• CNCT19 for Patients With Autoimmune Hemolytic Anemia After Failure ≥3 Lines of Therapy.Active, not recruitingNCT06231368Phase 1
• A Randomized, Double-blind, Placebo-controlled, and Multi-center Clinical Study of CM313 in the Treatment of Immune ThrombocytopeniaActive, not recruitingNCT06199089Phase 2
• A Study of c-Kit Mutation as MRD in Acute Myeloid LeukemiaWithdrawnNCT06116318
• Optimizing Induction Chemotherapy Regimens for ND Elderly AML Patients Who Are Eligible for Intense ChemotherapyActive, not recruitingNCT06066242Not applicable
• Natural Killer(NK) Cell Therapy in Acute Myeloid LeukemiaCompletedNCT05987696Phase 1
• Cyclophosphamide Added to Standard Immunosuppressive Therapy With Herombopag as Front-line Therapy in Patients With Severe Aplastic AnemiaActive, not recruitingNCT05975996Phase 2
• Mitoxantrone Hydrochloride Liposome Combined With Chemotherapy in Untreated de Novo Acute Myeloid LeukemiaCompletedNCT05941585Not applicable
• A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell LeukemiaActive, not recruitingNCT05870917Phase 2
• Evaluation the Safety and Efficacy of KL003 Cell Injection in the Treatment of Transfusion-dependent β-thalassemia.Active, not recruitingNCT05860595Not applicable
• A Study of VRd-based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With New-diagnosed Multiple MyelomaActive, not recruitingNCT05860036Phase 2
• A Study of VRd-based Regimen Combined With CART-ASCT-CART2 Treatment in NDMM Patients With P53 AbnormalitiesActive, not recruitingNCT05850286Phase 2
• BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCTWithdrawnNCT05846737Phase 2
• Efficacy of Daratumumab to Overcome Platelet Transfusion Refractoriness in Patients with Aplastic AnemiaCompletedNCT05832216Phase 1
• LILRB4 STAR-T Cell Therapy for Monocytic LeukemiaCompletedNCT05739409Not applicable
• Hetrombopag for the Enhancement of Platelet Engraftment After Allogeneic Hematopoietic Stem Cell TransplantationStatus unknownNCT05727917Not applicable
• Avatrombopag Combined With IST as First-line Treatment for SAAStatus unknownNCT05720234Phase 2
• A Prospective, One-arm and Open Clinical Study of CM313 in the Treatment of Immune ThrombocytopeniaCompletedNCT05694767Phase 2
• Efficacy and Safety of PI3K Inhibitors in Relapsed/Refractory Large Granular T Lymphocytic LeukemiaCompletedNCT05676710Phase 1
• PI3K Delta Inhibitor in Relapsed / Refractory Autoimmune Hemolytic Anemia Patients After Receiving Two or More Lines of TherapyTerminatedNCT05676697Phase 1
• Herombopag Added to Cyclosporine in Non Severe Aplastic AnemiaCompletedNCT05660785Phase 2
• The Application of Ursodeoxycholic Acid for the Prevention of SARS-CoV-2 Infection (COVID-19)CompletedNCT05659654Phase 1/2
• CLL-1/CD33 Targeted LCAR-AMDR Cells in Patients With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT05654779Phase 1
• A Study of Olverembatinib Combined With Inotuzumab Ozogamicin in the Treatment ph+ ALL With MRD Persistent PositiveStatus unknownNCT05603156Not applicable
• Natural Killer(NK) Cell Therapy for AML Minimal Residual DiseaseTerminatedNCT05601830Phase 1
• Natural Killer(NK) Cell Therapy for Acute Myeloid LeukemiaTerminatedNCT05601466Phase 1
• Prevention of Severe Acute Graft-versus-host Disease in Adult Patients Using a daGOAT ModelCompletedNCT05600855Phase 2
• Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for de Novo Ph+ ALLCompletedNCT05594784Phase 2
• A Randomized Trial Comparing Optimized rhTPO Treatment With Eltrombopag Treatment in Pre-treated ITP PtsCompletedNCT05583838Phase 4
• Efficacy and Safety of Avatrombopag Combined With IST for the Treatment of HAAA and SAA With Abnormal Liver FunctionStatus unknownNCT05571332Not applicable
• A Clinical Trial to Assess Safety and Efficacy of Daratumumab in the Treatment of Primary Immune ThrombocytopeniaActive, not recruitingNCT05562882Phase 2
• Anlotinib Hydrochloride Capsule Monotherapy and Combination Therapy Relapsed and Refractory Multiple MyelomaStatus unknownNCT05549973Phase 1
• Using Mass Spectrometry (EasyM) Detecting Minimal Residual Disease (MRD) in Multiple MyelomaStatus unknownNCT05536700
• A Study of PEG-rhG-CSF and rhG-CSF Used for Aplastic Anemia Granulocyte DeficiencyStatus unknownNCT05531279Not applicable
• Umbilical Cord Mesenchymal Stem Cells as First-line Treatment for Patients With Acute Graft Versus Host DiseaseStatus unknownNCT05531266Not applicable
• Efficacy and Safety of Inotuzumab Ozogamicin in Treating Adult Patients With Ph Negative ALL With Minimal Residual Disease Positive After Induction ChemotherapyActive, not recruitingNCT05456698Phase 2
• CD7 CAR-T for Patients With r/r CD7+ Hematologic MalignanciesCompletedNCT05454241Phase 2
• Efficacy and Safety of CSA and Avatrombopag for the Treatment of SAA in the ElderlyStatus unknownNCT05433922Not applicable
• Efficacy of Venetoclax Based Regimen in Prevention Relapse of Consecutive MRD Positive AML PatientsTerminatedNCT05361057Phase 2
• Intensive Therapy Combined With Venetoclax for Adult Acute Myeloid LeukemiaActive, not recruitingNCT05356169Phase 2/3
• Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation in Patients With Acute LeukemiaStatus unknownNCT05335226Not applicable
• Targeting CD19/CD20/CD22 Triple-targeted Cell in Patients With Relapsed/Refractory B-cell LymphomaTerminatedNCT05318963Phase 1
• GVM±R in Patients With Relapsed or Refractory Aggressive NHLActive, not recruitingNCT05299164Phase 1
• A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic LeukemiaTerminatedNCT05292898Phase 1
• Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLLStatus unknownNCT05287984Phase 2
• PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's LymphomaStatus unknownNCT05137886Phase 2
• Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALLTerminatedNCT05071482Phase 4
• Efficacy and Safety of Low-dose Decitabine in Refractory Aplastic AnemiaTerminatedNCT04854889Phase 2
• Posaconazole for Pulmonary Fungal Infection Prophylaxis in Hematopoietic Stem Cell Transplantation PatientsCompletedNCT04725942
• Allogeneic γδ T Cells Immunotherapy in r/r Non-Hodgkin's Lymphoma (NHL) or Peripheral T Cell Lymphomas (PTCL) PatientsStatus unknownNCT04696705Early Phase 1
• CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell LymphomaCompletedNCT04690192Phase 1/2
• Zanubrutinib, Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's MacroglobulinemiaCompletedNCT04463953Phase 2
• Bortezomib Plus Dexamethasone for Acquired Pure Red Cell Aplasia Failure or Relapse After First-line TreatmentCompletedNCT04423367Phase 2
• Efficacy of HAD Induction With Intensified Cytarabine in Newly-diagnosed CEBPA Double Mutated Acute Myeloid LeukemiaActive, not recruitingNCT04415008Phase 2
• The Safety and Efficacy of Ibrutinib in Refractory/Relapsed Autoimmune Hemolytic AnemiaActive, not recruitingNCT04398459Phase 2
• Safety and Efficacy Evaluation of ET-01 Transplantation in Subjects With Transfusion Dependent β-ThalassaemiaCompletedNCT04390971Not applicable
• A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple MyelomaCompletedNCT04322292Phase 1
• A Study of C-CAR066 in Subjects With r/r Diffuse Large B Cell Lymphoma Who Received CD19 CAR-T TherapyCompletedNCT04316624Phase 1
• Gene Therapy for Chinese Hemophilia BCompletedNCT04135300Not applicable
• Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell LymphomaCompletedNCT04067414Phase 1
• CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL)TerminatedNCT04034446Early Phase 1
• γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)Status unknownNCT04028440Early Phase 1
• Study of Human Umbilical Cord-derived Mesenchymal Stem Cells for Treatment of Refractory Immune ThrombocytopeniaCompletedNCT04014166Not applicable
• a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma PatientsStatus unknownNCT04008888Not applicable
• DLCL002 Protocol for Patients With High Risk Aggressive B-cell LymphomaStatus unknownNCT03837873Phase 2
• to Evaluate the Efficacy and Safety of Eltrombopag for Immune Thrombocytopenia With Chronic HBV InfectionCompletedNCT03664518Phase 2
• Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 MutationWithdrawnNCT03560908Phase 1
• Trial of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With RituximabCompletedNCT03384277Phase 4
• The Efficiency of CAMS (Chinese Academy of Medical Sciences)-2016 Trial for Pediatric Acute Myeloid LeukemiaStatus unknownNCT03173612Not applicable
• Efficacy Analysis of Comparison of CAMS（Chinese Academy of Medical Sciences）-2005 Trial and CAMS-2009 Trial for Pediatric Acute Myeloid LeukemiaCompletedNCT03165851
• Efficacy and Safety of Chidamide in CBF LeukemiaActive, not recruitingNCT03031262Phase 1/2
• CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell LymphomaCompletedNCT03029338Phase 1
• Efficacy of Decitabine in Clearance of MRDWithdrawnNCT03021395Phase 1/2
• Efficacy of Intermediate-Dose Cytarabine Induction Regimen in Adult AMLActive, not recruitingNCT03021330Phase 3
• CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic LeukemiaCompletedNCT02975687Phase 1
• Efficacy of Idarubicin, Cytarabine and Cyclophosphamide (IAC) Regimen in Relapsed/Refractory AMLCompletedNCT02937662Phase 2
• EDOCH Alternating With DHAP for New Diagnosed Younger MCLCompletedNCT02858804Phase 4
• Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenström MacroglobulinemiaCompletedNCT02844361Phase 4
• The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström MacroglobulinemiaCompletedNCT02844322Phase 4
• The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WMCompletedNCT02844309Phase 4
• Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic LeukemiaCompletedNCT02523976Phase 2
• Umbilical Cord Mesenchymal Stem Cells Injection for Peripheral Arterial DiseaseCompletedNCT02287831Phase 1/2
• Efficacy and Safety of rhTPO for the Treatment of Thrombocytopenia After Chemotherapy in AML PatientsCompletedNCT02267993Phase 4
• A Single-Arm Phase 2 Study With Optimized Standard Protocol for Severe Aplastic AnemiaCompletedNCT02203396Phase 2
• Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013)Status unknownNCT01760096Phase 2
• Low-dose Rituximab Regimens in Chinese Adult Patients With Immune ThrombocytopeniaCompletedNCT01719692Not applicable

← Institute of Hematology & Blood Diseases Hospital, China overview and focus areas